A transparent, rules-based read on the fundamentals — each pillar scored 0–100 from the metrics on this page. A starting point for research, not investment advice.
Trailing fundamentals and forward valuation at a glance.
Latest headlines mentioning Pfizer Inc..
Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Pfizer's Braftovi Regimen Cuts Risk of Progression, Death in Phase 3 Trial in Colorectal Cancer
How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers
SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor
3 Cash-Producing Stocks Worth Your Attention
Is Pfizer the Perfect Stock to Own with Kevin Warsh Heading the Fed?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
www.pfizer.comData via Polygon & Yahoo Finance. For research and educational purposes only — not investment advice. As of 6/2/2026, 2:22:04 AM.